Switch theme
Sign up to access all valuation multiples
Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market planĀ focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth planĀ for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.
1990
2.4K+
LTM Revenue $540M
LTM EBITDA $93.8M
$888M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Strides Pharma has a last 12-month revenue of $540M and a last 12-month EBITDA of $93.8M.
In the most recent fiscal year, Strides Pharma achieved revenue of $452M and an EBITDA of $43.7M.
Strides Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Strides Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $419M | $452M | XXX | XXX | XXX |
| Gross Profit | $167M | $221M | XXX | XXX | XXX |
| Gross Margin | 40% | 49% | XXX | XXX | XXX |
| EBITDA | $20.3M | $43.7M | XXX | XXX | XXX |
| EBITDA Margin | 5% | 10% | XXX | XXX | XXX |
| Net Profit | -$53.5M | -$23.5M | XXX | XXX | XXX |
| Net Margin | -13% | -5% | XXX | XXX | XXX |
| Net Debt | $304M | $287M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Strides Pharma's stock price is INR 615 (or $7).
Strides Pharma has current market cap of INR 56.7B (or $659M), and EV of INR 76.4B (or $888M).
See Strides Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $888M | $659M | XXX | XXX | XXX | XXX | $0.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Strides Pharma has market cap of $659M and EV of $888M.
Strides Pharma's trades at 1.6x LTM EV/Revenue multiple, and 9.5x LTM EBITDA.
Analysts estimate Strides Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Strides Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $888M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 11.0x | XXX | XXX | XXX |
| P/E | 20.3x | XXX | XXX | XXX |
| P/E/Growth | 0.4x | XXX | XXX | XXX |
| EV/FCF | 23.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpStrides Pharma's NTM/LTM revenue growth is 10%
Strides Pharma's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Strides Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Strides Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Strides Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 116% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 26% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 43% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Strides Pharma acquired XXX companies to date.
Last acquisition by Strides Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Strides Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Strides Pharma founded? | Strides Pharma was founded in 1990. |
| Where is Strides Pharma headquartered? | Strides Pharma is headquartered in India. |
| How many employees does Strides Pharma have? | As of today, Strides Pharma has 2.4K+ employees. |
| Who is the CEO of Strides Pharma? | Strides Pharma's CEO is Mr. Badree Komandur. |
| Is Strides Pharma publicy listed? | Yes, Strides Pharma is a public company listed on NSE. |
| What is the stock symbol of Strides Pharma? | Strides Pharma trades under STAR ticker. |
| When did Strides Pharma go public? | Strides Pharma went public in 2000. |
| Who are competitors of Strides Pharma? | Similar companies to Strides Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Strides Pharma? | Strides Pharma's current market cap is $659M |
| What is the current revenue of Strides Pharma? | Strides Pharma's last 12-month revenue is $540M. |
| What is the current EBITDA of Strides Pharma? | Strides Pharma's last 12-month EBITDA is $93.8M. |
| What is the current EV/Revenue multiple of Strides Pharma? | Current revenue multiple of Strides Pharma is 1.6x. |
| What is the current EV/EBITDA multiple of Strides Pharma? | Current EBITDA multiple of Strides Pharma is 9.5x. |
| What is the current revenue growth of Strides Pharma? | Strides Pharma revenue growth between 2023 and 2024 was 8%. |
| Is Strides Pharma profitable? | Yes, Strides Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
